-
1
-
-
0033530262
-
Chemotherapy-induced anemia in adults: Incidence and treatment
-
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 1616-1634
-
-
Groopman, J.E.1
Itri, L.M.2
-
2
-
-
20844434968
-
Cancer-related anemia: Pathogenesis, prevalence and treatment
-
Birgegård G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: Pathogenesis, prevalence and treatment. Oncology 2005; 68: 3-11.
-
(2005)
Oncology
, vol.68
, pp. 3-11
-
-
Birgegård, G.1
Aapro, M.S.2
Bokemeyer, C.3
-
3
-
-
5344263788
-
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
-
Ludwig H, Belle SV, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
-
(2004)
Eur J Cancer
, vol.40
, pp. 2293-2306
-
-
Ludwig, H.1
Belle, S.V.2
Barrett-Lee, P.3
-
4
-
-
67651146893
-
The anemia of inflammation/malignancy: Mechanisms and management
-
Adamson J. The anemia of inflammation/malignancy: Mechanisms and management. Am Soc Hematol Education Prog 2008; 1: 159-165.
-
Am Soc Hematol Education Prog
, vol.2008
, Issue.1
, pp. 159-165
-
-
Adamson, J.1
-
5
-
-
78649753411
-
Detection, evaluation, and management of iron-restricted erythropoesis
-
Goodnough L. Detection, evaluation, and management of iron-restricted erythropoesis. Blood 2010; 116: 4754-4761.
-
(2010)
Blood
, vol.116
, pp. 4754-4761
-
-
Goodnough, L.1
-
6
-
-
65449117261
-
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials
-
Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
-
(2009)
Lancet
, vol.373
, pp. 1532-1542
-
-
Bohlius, J.1
Schmidlin, K.2
Brillant, C.3
-
7
-
-
67649934442
-
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia
-
Ludwig H, Crawford J, Österborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27: 2838-2847.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2838-2847
-
-
Ludwig, H.1
Crawford, J.2
Österborg, A.3
-
8
-
-
75549086280
-
Erythropoiesis-stimulating agents in oncology: A study level meta analysis of survival and other safety outcomes
-
Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study level meta analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-315.
-
(2010)
Br J Cancer
, vol.102
, pp. 301-315
-
-
Glaspy, J.1
Crawford, J.2
Vansteenkiste, J.3
-
9
-
-
78751499254
-
FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp
-
U.S. Food and Drug Administration
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm#SA.
-
-
-
-
10
-
-
33646905411
-
Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
-
Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708-714.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 708-714
-
-
Bohlius, J.1
Wilson, J.2
Seidenfeld, J.3
-
11
-
-
73349121307
-
Anemia management in oncology and hematology
-
Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009; 14: 43-56.
-
(2009)
Oncologist
, vol.14
, pp. 43-56
-
-
Spivak, J.L.1
Gascón, P.2
Ludwig, H.3
-
12
-
-
40349103260
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
-
Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 2008; 299: 914-924.
-
(2008)
J Am Med Assoc
, vol.299
, pp. 914-924
-
-
Bennett, C.L.1
Silver, S.M.2
Djulbegovic, B.3
-
13
-
-
33646345152
-
KDOQI clinical practice guildelines and clinical practice recommendations for anemia in chronic kidney disease
-
Foundation NK. KDOQI clinical practice guildelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S1-S146.
-
(2006)
Am J Kidney Dis
, vol.47
-
-
Foundation, N.K.1
-
14
-
-
6344254701
-
Iron deficiency and thrombosis: Literature review
-
Keung Y-K, Owen J. Iron deficiency and thrombosis: Literature review. Clin Appl Thrombosis/Hemostasis 2004; 10: 387-391.
-
(2004)
Clin Appl Thrombosis/Hemostasis
, vol.10
, pp. 387-391
-
-
Keung, Y.-K.1
Owen, J.2
-
15
-
-
29144486069
-
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
-
Khorana A, Francis C, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822-2829.
-
(2005)
Cancer
, vol.104
, pp. 2822-2829
-
-
Khorana, A.1
Francis, C.2
Culakova, E.3
-
16
-
-
0028596458
-
Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: Correlation of platelet count with erythropoietic activity and iron parameters
-
Beguin Y, Loo M, R'Zik S, et al. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: Correlation of platelet count with erythropoietic activity and iron parameters. Eur J Haematol 1994; 53: 265-270.
-
(1994)
Eur J Haematol
, vol.53
, pp. 265-270
-
-
Beguin, Y.1
Loo, M.2
R'Zik, S.3
-
17
-
-
44649121569
-
Thrombosis with erythropoietic stimulating agents-Does iron-deficient erythropoiesis play a role?
-
Dahl NV, Henry D, Coyne DW. Thrombosis with erythropoietic stimulating agents-Does iron-deficient erythropoiesis play a role? Seminars Dialysis 2008; 21: 210-211.
-
(2008)
Seminars Dialysis
, vol.21
, pp. 210-211
-
-
Dahl, N.V.1
Henry, D.2
Coyne, D.W.3
-
18
-
-
33847046008
-
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy
-
Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242.
-
(2007)
Oncologist
, vol.12
, pp. 231-242
-
-
Henry, D.H.1
Dahl, N.V.2
Auerbach, M.3
-
19
-
-
43249124234
-
Should intravenous iron be the standard of care in oncology?
-
Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008; 26: 1579-1581.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1579-1581
-
-
Auerbach, M.1
-
20
-
-
79955031500
-
Parenteral iron therapy in cancer-associated anemia
-
Henry D. Parenteral iron therapy in cancer-associated anemia. Hematology 2010; 1: 351-356.
-
Hematology
, vol.2010
, Issue.1
, pp. 351-356
-
-
Henry, D.1
-
21
-
-
79951986687
-
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia
-
Steensma D, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011; 29: 97-105.
-
(2011)
J Clin Oncol
, vol.29
, pp. 97-105
-
-
Steensma, D.1
Sloan, J.A.2
Dakhil, S.R.3
-
22
-
-
84857055492
-
The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial
-
abstr 9031.
-
Steensma DP, Sasu BJ, Sloan JA, et al. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. J Clin Oncol 2011; 29( Suppl); abstr 9031.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Steensma, D.P.1
Sasu, B.J.2
Sloan, J.A.3
-
23
-
-
84873075963
-
-
Safety concerns associated with aranesp (Darbepoetin Alfa) Amgen, Inc. and Procrit (Epoetin Alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy.
-
Luksenburg H, Weir A, Wager R. Safety concerns associated with aranesp (Darbepoetin Alfa) Amgen, Inc. and Procrit (Epoetin Alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2_04_fda-aranesp-procrit.htm.
-
-
-
Luksenburg, H.1
Weir, A.2
Wager, R.3
-
24
-
-
79955024469
-
Iron supplementation to treat anemia in patients with chronic kidney disease
-
Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010; 6: 699-710.
-
(2010)
Nat Rev Nephrol
, vol.6
, pp. 699-710
-
-
Besarab, A.1
Coyne, D.W.2
-
25
-
-
33947212276
-
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study
-
Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007; 18: 975-984.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 975-984
-
-
Coyne, D.W.1
Kapoian, T.2
Suki, W.3
-
26
-
-
69549104049
-
Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy
-
Kuderer N, Khorana A, Francis C. Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy. Blood 2008; 112: 172.
-
(2008)
Blood
, vol.112
, pp. 172
-
-
Kuderer, N.1
Khorana, A.2
Francis, C.3
|